研究文章
生殖系BRCA1和BRCA2的突变在乳腺癌患者高遗传风险在土耳其人口
|
| 特征 |
n |
BRCA1和BRCA2 |
乳腺癌易感基因1 |
BRCA2 |
| 负 |
积极的 |
负 |
积极的 |
p |
负 |
积极的 |
p |
|
| 年龄(平均(min-max)] |
|
46 (28 - 82) |
43.7 (27 - 63) |
45.7 |
45.5 |
0.781 |
46.0 |
41.4 |
0.190 |
| 生殖系基因突变 |
|
81例(81%) |
19 (19%) |
88例(88%) |
11 (11%) |
|
91例(91%) |
8 (8%) |
|
| 家族病史 |
21 |
17 (81%) |
4 (19%) |
19 (90.5%) |
2 (9.5%) |
1.000 |
19 (90.5%) |
2 (9。5%) |
1.000 |
| 双边乳腺癌 |
7 |
6 (86%) |
1 (14%) |
7 |
0 |
0.351 |
6 (86%) |
1 (14%) |
1.000 |
| 乳房+卵巢癌 |
7 |
4 (67.2%) |
3 (42.8%) |
5 (71.5%) |
2 (28.5%) |
0.173 |
6 (85.8%) |
1 (14.2%) |
0.456 |
| 三阴性肿瘤 |
33 |
25 (75.7%) |
8 (24.2%) |
27 (81.8%) |
6 (18.1%) |
0.172 |
31 (93.9%) |
2 (6.0%) |
0.715 |
| 40岁以下 |
41 |
33 (80.4%) |
8 (19.5%) |
37 (90.2%) |
4 (9.5%) |
1.000 |
37 (90.2%) |
4 (9.5%) |
0.715 |
| 三负+ 40岁以下 |
8 |
5 (62.5%) |
3 (37.5%) |
6 (75%) |
2 (25%) |
|
7 (87.5%) |
1 (12.5%) |
|
| 雌激素受体阳性 |
60 |
51 (85%) |
9 (15%) |
56 (93.3%) |
4 (6.6%) |
0.316 |
55 (91.6%) |
5 (8.33%) |
0.824 |
| ER阴性 |
39 |
29 (74.3%) |
10 (25%) |
32 (82%) |
7 (17.9%) |
36 (92.3%) |
3 (7.6%) |
| 公关的积极 |
53 |
45 (84.9%) |
8 (15%) |
49 (92.4%) |
4 (7.5%) |
0.526 |
49 (92.4%) |
4 (7.5%) |
1.000 |
| 公关负 |
46 |
35 (76%) |
11 (23.9%) |
39 (84.7%) |
7 (15.2%) |
42 (91.3%) |
4 (8.6%) |
| 她2积极 |
10 |
10 (100%) |
0 |
10 (100%) |
0 |
0.650 |
10 (100%) |
0 |
1.000 |
| 右乳房 |
47 |
36 (76.5%) |
11 (23.4%) |
39 (82.9%) |
8 (17%) |
0.262 |
44 (93.6%) |
3 (6.3%) |
0.710 |
| 左胸 |
45 |
37 (82.2%) |
8 (17.7%) |
42 (93.3%) |
3 (6.6%) |
40 (88.8%) |
5 (11.1%) |
| 浸润性导管癌 |
86年 |
69例(80%) |
17 (19%) |
75例(87%) |
11 (12%) |
0.351 |
80例(93%) |
6 (6.9%) |
0.245 |
| 浸润性小叶癌 |
10 |
9 (90%) |
1 (10%) |
10 |
0 |
0.596 |
9 (90%) |
1 (10%) |
0.583 |
|
|
